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Abstract: Fosaprepitant is a prodrug of aprepitant, a neurokinin1 (NK1) receptor antagonist 
used in prophylactic antiemetic regimens used prior to cytotoxic chemotherapy. Fosaprepitant 
is being developed to provide a parenterally administered alternative to the orally administered 
aprepitant. Fosaprepitant is rapidly converted to aprepitant and an intravenous dose of 115 mg is 
bioequivalent to 125 mg orally, with similar plasma concentrations at 24 hours. In phase I and 
II trials fosaprepitant shows efﬁ  cacy, but the large randomized efﬁ  cacy studies have utilized 
aprepitant. When it is added to dexamethasone and a 5HT3 receptor antagonist on day 1 prior 
to chemotherapy aprepitant improves the control of acute post chemotherapy emesis and when 
continued on days 2 and 3 with dexamethasone it demonstrated even greater improvement in 
the control of delayed emesis. This has been shown with both cisplatin-containing regimens 
and those based upon cyclophosphamide and an anthracycline. Fosaprepitant is well tolerated 
with mild to moderate venous irritation being the only additional toxicity to those seen with oral 
aprepitant, and that is a function of dose, concentration, and infusion rate. Headaches are the 
other toxicity most commonly reported. Fosaprepitant can be used as a parenteral alternative 
to aprepitant in regimens to control chemotherapy-induced emesis.
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Introduction
The introduction of cytotoxic chemotherapy, and particularly cisplatin, was associated 
with nausea and vomiting that did not respond to conventional doses of the then avail-
able antiemetics, exempliﬁ  ed by metoclopramide and prochlorperazine. Of the factors 
that predicted nausea and vomiting the most signiﬁ  cant was the cytotoxic drug, as 
each drug displayed a different emetic potential, and there were different mechanisms 
by which the cytotoxics could cause vomiting (Andrews et al 1998; Hesketh 1999). 
The most common pattern of nausea and vomiting is acute emesis which commences 
within hours of receiving chemotherapy and lasts over the ﬁ  rst 24 hours. This can be 
followed by delayed emesis commencing near the beginning of the ﬁ  rst day and often 
lasting for at least 5 days (Kris et al 1985). Those patients who experience severe post-
chemotherapy emesis are then prone to developing anticipatory emesis as a conditioned 
response (Morrow 1982). Patients who have poor control of post chemotherapy emesis 
also demonstrate deterioration in their quality of life (Osoba et al 1997).
It was the discovery that two important mechanisms for post-chemotherapy emesis 
were mediated through 5 hydroxytryptamine3 (5HT3) and neurokinin1 (NK1) receptors 
and the development of antagonists that saw a great impact made upon the control of 
chemotherapy-induced vomiting and to a lesser extent nausea. The 5HT3 receptors, 
predominantly in the small bowel, were major mediators of acute emesis, and the ﬁ  rst 
of the antagonists, ondansetron, when given prior to chemotherapy, revolutionized the 
control of post chemotherapy acute emesis. Ondansetron and dexamethasone controlled 
acute emesis in over 80% patients (Gralla et al 1999). Patients, however, were still Therapeutics and Clinical Risk Management 2008:4(2) 502
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listing nausea and vomiting in their top three side effects even 
after the great improvement in the control of acute emesis 
(Boer-Dennert et al 1997). This was due to the incidence of 
delayed emesis which can occur in 20%–25% patients in the 
absence of acute emesis, and which was being underestimated 
by clinicians by up to 30% (Grunberg et al 2004).
Unfortunately, in only 50% patients was the delayed 
phase of emesis, caused by drugs such as cisplatin, controlled 
by ondansetron and dexamethasone. It was the dexametha-
sone that was the most active drug, suggesting that a different 
mechanism was responsible for delayed compared with acute 
emesis (Olver et al 1996).
Substance P, a tachykinin, binds to NK1 receptors in the 
brain stem which send messages to the vomiting center and 
induce vomiting. Blocking the NK1 receptor lessens vom-
iting after cisplatin, and a variety of other emetic stimuli 
(Diemunsch and Grelot 2000).
With the development of the orally active NK1 receptor 
antagonist, aprepitant, it was found that when it was added 
to ondansetron and dexamethasone it improved the control 
of cisplatin-induced acute emesis, but when continued for 2 
further days had a major impact on the control of the delayed 
phase of the post-chemotherapy emesis (Hesketh et al 2003; 
Poli-Bigelli et al 2003).
Fosaprepitant (L-758,298 or MK-0517) is a prodrug of 
aprepitant that can be administered intravenously and is con-
verted into aprepitant within 30 minutes (Navari 2007).
The pharmacology of fosaprepitant
Fosaprepitant dimeglumine is a white powder which is freely 
water soluble and is a phosphoryl prodrug of aprepitant 
(Hale et al 2000). Its antiemetic properties are attributable 
to aprepitant, which is a selective neurokinin 1 (NK1) recep-
tor antagonist with low afﬁ  nity for NK2 and NK3 receptors 
(Watson et al 1998). It inhibits chemotherapy emesis by 
penetrating the brain and occupying central NK1 receptors 
for a sufﬁ  cient duration to inhibit both the acute and delayed 
phases of emesis (Tattersall et al 2000). Antiemetic efﬁ  cacy 
with aprepitant increases with receptor occupancy up until 
a dose of 125 mg orally, but there is no greater beneﬁ  t with 
higher doses (Hargreaves 2002).
Fosaprepitant 115 mg given intravenously is bioequiva-
lent to aprepitant 125 mg given by mouth with similar plasma 
concentrations at 24 hours (Merck and Co Inc 2007). It has 
been trialed in single daily doses for up to 4 days. Fosa-
prepitant is converted to aprepitant within 30 minutes after 
the end of an infusion. Aprepitant is 95% bound to plasma 
proteins. In vitro studies show that aprepitant is metabolized 
in the liver primarily by CYP3A4, with minor metabolism 
by CYP1A2 and CYP2C19.
Preclinical toxicology studies of bolus fosaprepitant 
administered in seconds to dogs and rats showed that con-
centrations of  1 mg/mL were well tolerated. Concentrations 
up to 25 mg/ml at low doses (2–4 mg/kg/day) were well 
tolerated in dogs but intermediate concentrations (10 mg/mL) 
given at higher doses (32 mg/kg/day) caused venous irritation 
(Lasseter et al 2007).
There have been seven metabolites identiﬁ  ed in human 
plasma, which are only mildly active. Following a single 
intravenous dose of 14C-labeled fosaprepitant 57% of 
the radioactivity was recovered in the urine and 45% 
in the feces. The terminal half-life of aprepitant following 
the administration of aprepitant is around 14 hours (Merck 
and Co Inc 2007).
No dose adjustment is considered necessary based on 
gender, race, or age although there are no data available for 
fosaprepitant in patients less that 18 years old. Based on phar-
macokinetics no dose adjustment is required for severe renal 
insufﬁ  ciency including those patients on dialysis (Bergman 
et al 2005). Similarly there is no clinically meaningful dif-
ference in the pharmacokinetic parameters patients with mild 
to moderated hepatic insufﬁ  ciency (Child-Pugh score 7–9) 
and no data on severe hepatic insufﬁ  ciency.
Drug interactions
As a moderate inhibitor of CYP3A4, fosaprepitant/aprepitant 
should not be co-administered with drugs such as pimozide, 
terfenadine, astemizole, or cisapride where the inhibition 
may result in elevated concentrations of these drugs, with 
serious consequences. Similar care should be taken with 
drugs with a narrow therapeutic index that are metabolized 
by CYP3A4 such as cyclosporine, sirolimus, and tacrolimus. 
As fosaprepitant/aprepitant induces the metabolism of drugs 
metabolized by CYP2C9, the co-administration with drugs 
metabolized by this mechanism such as warfarin should 
be monitored carefully (Depre et al 2005). This is also the 
case for tolbutamide and phenytoin, which may result in them 
achieving lower plasma concentrations than desirable. The 
concentrations of oral contraceptives may be decreased with 
co-administration of aprepitant, so alternate contraception 
should be used.
Of the drugs to be given with fosaprepitant, there is no 
evidence of clinically meaningful interactions with 5HT3 
antagonists, including palonosetron (Blum et al 2003; 
Shah et al 2005). There are a number of chemotherapy 
agents metabolized by CYP3A4 such as taxanes, etoposide, Therapeutics and Clinical Risk Management 2008:4(2) 503
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irinotecan, ifosfamide, imatininb, and vinca alkaloids. Oral 
aprepitant did not inﬂ  uence the pharmacokinetics of docetaxel 
or vinorelbine and there has been no obvious interaction 
clinically when administered with etoposide, vinorelbine and 
paclitaxel (Nygren et al 2005; Loos et al 2007). Aprepitant 
does inhibit cyclophosphamide bioactivation and thiotepa 
metabolism, but the effects are small (de Jonge et al 2005).
Aprepitant increases the AUC of dexamethasone, a sub-
strate of CYP3A4 2.2 fold; therefore the co-administered 
doses of dexamethasone should be halved, as was done in the 
two phase III trials that established the efﬁ  cacy of aprepitant 
in preventing high-dose cisplatin-induced emesis (McCrea 
et al 2003).
Drugs such as rifampicin and St John’s Wort, strong 
CYP3A4 inducers, reduce the concentration of aprepitant/
fosaprepitant whereas a strong CYP3A4 inhibitor like keto-
conazole can increase the AUC of aprepitant ﬁ  ve-fold. Food 
effects on the absorption of aprepitant are minimized because 
of its nanoparticle formulation (Olver et al 2007).
Early phase clinical trials 
of fosaprepitant
In the initial development of aprepitant, two of the phase II 
trials used the intravenous prodrug L-758298, now called 
fosaprepitant. These trials were conducted in patients who 
were receiving their ﬁ  rst ever dose of at least 50 mg/m2 cis-
platin, which without antiemetic prophylaxis will be associ-
ated with acute nausea and vomiting in 100% of patients and 
delayed vomiting in up to 70% of patients (Kris et al 1996). 
In the ﬁ  rst of these fosaprepitant at a dose of either 60 mg or 
100 mg was compared with ondansetron 32 mg given 1 hour 
before the chemotherapy. There was no signiﬁ  cant difference 
in acute postchemotherapy emesis, with 37% on fosaprepitant 
and 52% on ondansetron having no emesis. In the delayed 
phase, 72% receiving fosaprepitant had no emesis compared 
with 30% receiving ondansetron (Cocquyt et al 2001).
In the next study, fosaprepitant was studied in combina-
tions. One group of patients received fosaprepitant 100 mg 
with intravenous dexamethasone 20 mg on day 1 and then 
oral aprepitant (MK-869) 300 mg on days 2 to 5. The second 
group had the same drugs on day 1 and placebo on days 2 
to 5 and the third group received intravenous ondansetron 
32 mg added to dexamethasone on day 1 and placebo on days 
2 to 5. Acute emesis was best controlled by the ondansetron 
and dexamethasone group (83%) compared with only 40% 
when the fosaprepitant groups were combined. However, 
the fosaprepitant groups did better in the delayed phase of 
the emesis with complete responses recorded for group 1 in 
59%, for group 2 in 46%, and for group 3 in 38% (p   0.05 
group 1 vs group 3) (van Belle et al 2002). These trials sug-
gested that NK1 receptor antagonists were going to be best 
in combination antiemetic regimens.
Later, fosaprepitant was developed as an alternativee 
intravenous formulation to oral aprepitant. A study was 
performed to ﬁ  nd the bioequivalent dose of fosaprepitant, in 
a polysorbate 80 vehicle, in terms of aprepitant AUC (area 
under the concentration time curve) to 125 mg aprepitant 
(Lasseter et al 2007). The study was in 3 parts. In parts 1 and 
2 fosaprepitant doses from 90 to 150 mg were investigated, 
and based on those results 2 doses of fosaprepitant, 100 
and 115 mg, were selected for the randomized open label 
crossover test of bioequivalence in part 3. Blood samples 
were collected over 72 hours following the drug adminis-
tration for aprepitant assays. Patients ranged in age from 18 
to 45 years. Across all three parts of the study 106 subjects 
received fosaprepitant doses ranging from 90 to 150. There 
were no subjects discontinued because of adverse events. In 
parts 1 and 2 neither the 150 mg dose nor the 90 mg dose 
met the AUC bioequivalence criteria relative to 125 mg 
aprepitant. The 115 mg dose proved bioequivalent to apre-
pitant. It is rapidly converted to aprepitant with a half-life in 
the plasma of 2.3 minutes and complete conversion occurs 
within 30 minutes. It is not extensively distributed to the tis-
sues. Although fosaprepitant resulted in a higher maximum 
concentration than aprepitant, the trough concentrations at 
24 hours were equivalent, suggesting similar NK1 receptor 
occupancy. This suggests that fosaprepitant 115 mg can be 
used interchangeably with 125 mg aprepitant.
Efﬁ  cacy
The efﬁ  cacy data come from the trials of aprepitant. Ini-
tially there were 3 other phase II studies with aprepitant. A 
351-patient placebo-controlled study in cisplatin-induced 
emesis studied 4 groups: the ﬁ  rst used granisetron and dexa-
methasone on day 1 with placebo days 2 to 5; the second 
added in aprepitant on day 1 and then 2 to 5; the third arm 
used aprepitant the day before chemotherapy and then with 
dexamethasone on day 1 but without the granisetron, and 
then continued aprepitant days 1 to 5; and the ﬁ  nal arm was 
similar but with the aprepitant and dexamethasone starting 
on day 1 (Campos et al 2001). This trial conﬁ  rmed the need 
for a 5HT3 antagonist as part of triple therapy on day 1 for 
controlling the acute phase of emesis and conﬁ  rmed the 
beneﬁ  t of aprepitant in delayed emesis.
In a further phase II study of 159 patients, granisetron and 
dexamethasone was the standard treatment with other groups Therapeutics and Clinical Risk Management 2008:4(2) 504
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adding aprepitant to this on day 1, then either continuing 
aprepitant until day 5 or using placebo form days 2 to 5 
(Navari et al 1999). There was a signiﬁ  cantly superior result 
for acute emesis in the two groups who received triple therapy 
on day 1 (93% and 94% for complete control of emesis 
vs 67% p   0.001) and in the delayed phase those groups 
receiving aprepitant were signiﬁ  cantly better (82% and 78% 
vs 33%, p   0.001) although the difference between just 
day 1 aprepitant and daily dosing for 5 days did not reach 
statistical signiﬁ  cance.
A further phase II was designed to reﬁ  ne the dosing 
of aprepitant, adding to ondansetron plus dexamethasone 
125 mg aprepitant on day 1 and 80 mg days 2 to 5 compared 
with 40 mg on day 1 then 25 mg on days 2 to 5 or placebo 
(Chawala et al 2003). Again the patients receiving aprepi-
tant had superior control of acute and delayed emesis, but 
nausea was only better controlled in the delayed phase. The 
125/80 mg dosing schedule yielded superior efﬁ  cacy.
The efﬁ  cacy of aprepitant was proven deﬁ  nitively in 2 
phase II trials in patients receiving their ﬁ  rst ever dose of 
cisplatin  70 mg/m2 over  3 hours. The standard therapy 
was considered as ondansetron and dexamethasone on day 
1 followed by dexamethasone on days 2 to 4. The aprepitant 
arms added 125 mg of oral aprepitant on day 1 and then 
80 mg days 2 and 3 giving just the dexamethasone on day 4 
(Hesketh et al 2003; Poli-Bigelli et al 2003). Recording the 
Poli-Bigelli study ﬁ  rst then the Hesketh study, the aprepi-
tant arms were statistically signiﬁ  cantly superior in overall 
complete response rates (62.7% vs 43.3%, p   0.001 and 
72.1% vs 52.3%, p   0.001) and for acute emesis (82.8% 
vs 68.4%, p   0.001 and 89.2% vs 78.1%, p   0.001). 
However, the most impressive response differences were 
in delayed emesis (67.7 % vs 46.8%, p   0.001 and 74.4% 
vs 55.8%, p   0.001). Again, nausea was better controlled 
only in the delayed phase. The efﬁ  cacy of aprepitant was 
maintained over 6 cycles.
A speciﬁ  c study of multiple cycles of high-dose cisplatin 
used ondansetron and dexamethasone for the acute phase 
and compared a placebo for the delayed phase with two 
different dosing schedules of aprepitant on days 1 to 5 (de 
Wit et al 2003). The complete response rate was maintained 
over 6 cycles in the aprepitant groups but not in the placebo 
group.
In randomized studies, the selection of the control arm 
is vital. Given that it had been common practice to continue 
the 5HT3 antagonist with the dexamethasone for 4 days, a 
study in 489 patients receiving high-dose cisplatin random-
ized them to either ondansetron and dexamethasone for on 
each day or triple therapy with aprepitant on day 1 followed 
by aprepitant and dexamethasone as given in the large ran-
domized trials (Schmoll et al 2006). The aprepitant regimen 
yielded a signiﬁ  cantly improved 5-day overall response 
rate (72% vs 61%, p = 0.003) with a 9% improvement in 
protection from nausea and vomiting on day 1 and 11% on 
days 2 to 5.
Following the studies with cisplatin-containing regimens, 
the efﬁ  cacy of adding aprepitant to other chemotherapy 
regimens was trialed. In a large study 866 patients who were 
treated with cyclophosphamide and anthracylines, which 
as single agents have moderated emetic potential but as a 
combination arguably are of high emetic potential, were 
studied (Warr et al 2005). Patients were given oral ondan-
setron and dexamethasone with either aprepitant on days 
1, 2, and 3 or just followed by 2 days of ondansetron. The 
overall 5-day complete response rate was (50.8% vs 42.5%, 
p = 0.015) in favor of the aprepitant group. Nausea was not 
as well controlled as vomiting particularly in the delayed 
phase. The improved efﬁ  cacy was maintained over 4 cycles 
of chemotherapy (Herrstedt et al 2005).
In a small trial, the role of aprepitant as a salvage therapy 
to add into the antiemetic regimen in subsequent cycles if 
patients had failed to respond to a 5HT3 receptor antagonist 
and dexamethasone was tested for both cisplatin and other 
chemotherapy (Oechsle et al 2006). The addition of aprepi-
tant signiﬁ  cantly improved activity.
There are no large studies of the efﬁ  cacy of aprepitant in 
children or adolescents but case reports in adolescents are 
promising (Smith et al 2005).
As other new antiemetics are developed, combinations 
with aprepitant are tested. Palonosetron is a 5HT3 receptor 
antagonist with a longer duration of activity which has been 
reported as having better activity against the delayed emesis 
associated with chemotherapy of moderate emetic potential. 
After determining that there were no pharmacokinetic prob-
lems with the combination, aprepitant with palonosetron 
and dexamethasone was found to be highly effective in 
preventing chemotherapy-induced nausea and vomiting in 
the days following the administration of cyclophosphamide 
chemotherapy of moderate emetic potential (Shah et al 2005; 
Grote et al 2006).
Safety and tolerability
Fosaprepitant and aprepitant are very well tolerated. In the 
initial phase 1 studies with aprepitant or its prodrug the 
adverse events that were reported more commonly for aprepi-
tant groups over placebo were fatigue, somnolence, dizziness, Therapeutics and Clinical Risk Management 2008:4(2) 505
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ﬂ  ushing, nausea, hiccups, headache, and menstrual problems. 
In the trials of L-758298 compared with ondansetron the 
only signiﬁ  cant difference in toxicities was more diarrhoea 
with the prodrug than ondansetron, which itself would tend 
toward producing constipation (Cocquyt et al 2001; van Belle 
et al 2002). Most studies administered aprepitant as part of 
an antiemetic regimen which often included 5HT3 receptor 
antagonists, so it has been difﬁ  cult to isolate the side effects 
speciﬁ  cally due to aprepitant. In the two large phase III tri-
als the incidence of drug-related side adverse events for the 
aprepitant arm was 19.5% vs 14.4% in the control arm in 
the Poli-Bigelli study and 14.6% vs 11.0% in the Hesketh 
study (Hesketh et al 2003; Poli-Bigelli et al 2003). The 
most reported side effects were asthenia, anorexia, diarrhea, 
headaches, and hiccups. In the Warr study there was more 
constipation in the control arm and more dyspepsia in the 
aprepitant arm (Warr et al 2005).
In the study to establish the bioequivalence of fosapre-
pitant there were no serious adverse events or laboratory 
toxicities (Lasseter et al 2007). Headache and infusion site 
symptoms were the most reported events, but these were only 
of mild to moderate intensity. Fosaprepitant is tolerable at 
1 mg/mL infused over 15 to 30 minutes but was found to 
cause irritation at 25 mg/mL at doses of 50 mg or 100 mg 
infused over 30 seconds.
Patient quality of life and satisfaction
The impact on patients of chemotherapy-induced nausea 
and vomiting goes beyond those side effects to be associated 
with a measurable deterioration in their global quality of life 
(Osoba et al 1997). More speciﬁ  cally the patients experienc-
ing emesis also have more fatigue, anorexia, and insomnia.
In the large phase III trials of aprepitant in combination 
regimens for cisplatin and non-cisplatin induced emesis, a 
quality of life scale, the Functional Living Index Emesis 
(FLIE), was used (Martin et al 2003). The arms of the studies 
that contained aprepitant reported minimal or no impact of 
the emesis on daily life compared with those just receiving 
a 5HT3 antagonist and dexamethasone (74.4% vs 63.5% in 
the Poli-Bigelli study and 70.4% vs 55.6% in the Hesketh 
study) (Hesketh et al 2003; Poli-Bigelli et al 2003). In sub-
group analyses this improvement in maintaining daily life 
activities was independent of sex and independent of age (Ma 
et al 2003; Martin et al 2003; Hesketh et al 2006). A similar 
outcome was reported in the Warr study where cyclophospha-
mide and an anthracycline was the chemotherapy, and those 
reporting minimal or no impact of emesis and quality of life 
were 63.5% on aprepitant vs 55.6% without, p = 0.019).
Cost effectiveness is also an important consideration 
for patients. It has been calculated that the routine use of 
aprepitant in antiemetic prophylaxis is cost effective in those 
situations where the likelihood of delayed emesis is high or 
the need will exist later for costly rescue medications (Moore 
et al 2007).
Conclusions
Fosaprepitant, a prodrug of aprepitant, is being developed as an 
intravenous alternative to oral aprepitant. It is rapidly converted 
to aprepitant after administration. The efﬁ  cacy is the same as 
that of aprepitant. It is very well tolerated, with venous irrita-
tion being speciﬁ  c to this formulation and headache being the 
most frequent of the other toxicities. It seems that it is able to 
be used interchangeably with aprepitant and has been safely 
administered in single- and multiple-day schedules.
For example, in triple antiemetic therapy, fosaprepitant 
could be administered on day 1 with other antiemetics before 
intravenous chemotherapy and then on days 2 and 3 the 
NK1 therapy could be continued with oral aprepitant. An 
intravenous formulation may be more convenient in some 
circumstances and in some jurisdictions there are differing 
reimbursements for intravenous and oral drugs which may 
make an intravenous formulation more desirable, particu-
larly if the income was being used to fund additional patient 
services.
Medical indications would include patients with severe 
mucositis or difﬁ  culty swallowing or any gastrointestinal 
disturbance that would make oral therapy problematic.
Fosaprepitant provides an intravenous alternative to 
oral formulations of NK1 receptor antagonists that is safe 
and effective.
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